NSAIDs were associated with increased risk for mortality or recurrent MI in patients who had previous MI
- Short- and long-term treatment with non-steroidal anti-inflammatory drugs increases risk of death or recurrent MI in those with previous MI. Chakrabarti, Anjan K.; Gibson, C. Michael // Evidence Based Medicine;Apr2012, Vol. 17 Issue 2, p61
The article discusses the implications of non-steroidal anti-inflammatory drugs (NSAIDs) in causing negative cardiovascular outcomes among patients with prior myocardial infarction (MI). It highlights the association of the risk of death or recurrent MI with the short-term and long-term...
- NSAIDS Post Myocardial Infarction. Crawford, Michael H. // Clinical Cardiology Alert;Dec2012, Vol. 31 Issue 12, p95
An abstract of the article "Long term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: A nationwide cohort study" by A. M. Oslen and colleagues, as also a commentary on the same are presented.
- Influence of hyperbaric oxygenation treatment (HBOT) on clinical outcomes (recurrent myocardial infarction and survival rate) during five-year monitoring period after acute myocardial infarction. Dotsenko, Eduard; Salivonchyk, Dmitry; Menizibeya Welcome, Osain; Dotsenko, Konstantin; Salivonchyk, Sergei; Bobkov, Valery; Nikulina, Natalia; Semeniago, Eugenia; Nerobeeva, Svetlana // Health (1949-4998);Jan2014, Vol. 6 Issue 1, p51
Surgical treatments of acute myocardial infarction (MI) possess a high clinical effectiveness, but there are fixed limitations, related to the patient's state, which are limited by medical resources and organizational problems. The development of new medical technologies provides a better and...
- Cyclophosphamide in steroid-dependent nephrotic syndrome. Azib, Sonia; Macher, Marie; Kwon, Theresa; Dechartres, Agnes; Alberti, Corinne; Loirat, Chantal; Deschênes, Georges; Baudouin, Véronique // Pediatric Nephrology;Jun2011, Vol. 26 Issue 6, p927
In order to determine the long-term effects of cyclophosphamide (CPO) and to identify parameters associated with sustained remission, we retrospectively studied the data from 90 patients with steroid-dependent nephrotic syndrome (SDNS) who received a single course of oral cyclophosphamide (2...
- Avoid NSAIDs after Myocardial Infarction. Boyle, Andrew J. // Clinical Cardiology Alert;Jul2011, Vol. 30 Issue 7, p49
The article reports a Danish study by A. M. Schjerning-Olsen and colleagues which evaluated the effects of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the duration of its use in adults after their first myocardial infarction (MI). The study concluded that even short-term...
- Adding short-term androgen-deprivation therapy to radiotherapy improved survival in localized prostate cancer. Canfield, Steven E. // ACP Journal Club;11/15/2011, Vol. 155 Issue 5, p6
The article presents a study which examined whether adding short-term androgen-deprivation therapy (ADT) to radiotherapy (RDT) improves survival of patients with prostate cancer. It was found that acute and late hepatic toxic effects occurred in 29 percent and 6 percent of ADT plus radiotherapy...
- NSAIDS Post Myocardial Infarction. Crawford, Michael H. // Hospital Medicine Alert;Jan2013, Vol. 7 Issue 11, p84
An abstract of the article "Long term cardiovascular risk of non-steroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction: A nationwide cohort study," by A. M. Olsen and colleagues is presented.
- Income inequality and 30 day outcomes after acute myocardial infarction, heart failure, and pneumonia: retrospective cohort study. Lindenauer, Peter K.; Lagu, Tara; Rothberg, Michael B.; Avrunin, Jill; Pekow, Penelope S.; Yongfei Wang; Krumholz, Harlan M. // BMJ: British Medical Journal;3/9/2013, Vol. 346 Issue 7898, p15
The article discusses a study that reveals patients hospitalized with acute myocardial infarction, heart failure, and pneumonia, are exposed to high level of income inequality which were associated with an increased risk of readmission, but not mortality.
- 2013 - Apixaban reduced recurrence and did not increase major bleeding in previously treated VTE. Moll, Stephan // ACP Journal Club;4/16/2013, Vol. 158 Issue 8, p1
The article presents a randomized and double-blind study which was carried out analyze whether Apixaban, an oral factor inhibitor, can be used for the treatment of venous thromboembolism. In the study, two doses of Apixaban were compared with placebo in patients and who had completed six-12...